SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to significant price movement and high trading volume, sparking discussions about a potential short squeeze. The community is actively debating entry points, profit-taking strategies, and whether the stock will continue its upward trajectory, drawing comparisons to other high-flying stocks. Some traders are pointing to the company's low float and recent focus on AI-powered robotics as potential catalysts for continued momentum.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation that the Trump administration may soon reclassify marijuana, potentially as early as Monday, sparking excitement within the cannabis sector. The community is actively discussing the implications of this potential policy change on US-based cannabis companies and debating whether this time the long-awaited catalyst will finally materialize. Some traders are wary of previous false alarms, while others are eagerly anticipating a substantial re-rating of cannabis stocks.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim results from its RAD 101 Phase 2b imaging trial, showing promise in brain metastases diagnosis, with a webinar scheduled for further discussion. The community is actively discussing the potential for a short squeeze and significant price movement based on this news and the company's upcoming webinar. Some traders are pointing to the company's cash runway and potential for acquisition, while others express concern about potential dilutions and recent trading volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock makes new 2025 highs, with community members discussing its potential to reach $500 amidst debate on the company's valuation and Elon Musk's influence. Speculation around Tesla's autonomous driving advancements and the potential for a SpaceX IPO are also fueling the conversation, alongside concerns about the company's fundamentals.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation surrounding potential U.S. cannabis rescheduling following comments from President Trump, fueling community discussions about executive action and its potential impact. Traders are debating the likelihood and timing of any formal announcement, as well as the potential for a short squeeze. Community members are actively discussing the stock's price movement, potential catalysts, and trading strategies.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to concerns about slower growth, with community members pointing to recent CFO commentary at a conference and an analyst downgrade as potential drivers for price suppression. Despite this, some are optimistic about PayPal's fundamentals, aggressive buybacks, and strategic moves into areas like banking and stablecoins, viewing the negative sentiment as a contrarian buying opportunity. Community members are discussing the potential for a turnaround and the possibility of a short squeeze.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest a significant EV write-down and a strategic shift towards hybrid vehicles, which is being interpreted by some as a pragmatic move to focus on profitability and align with current market demand. The community is actively discussing the implications of this shift, with debates around whether it signals a retreat from EVs or a necessary adjustment in a challenging market landscape. Amidst the EV strategy recalibration, analysts are weighing in, setting price targets and evaluating Ford's potential to capitalize on policy shifts favoring domestic production.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions about its AI strategy and a potential acquisition, sparking mixed community sentiment.  Some believe NOW is well-positioned to benefit from AI, while others express concerns about market share and valuation.  The stock's recent price decline and high trading volume are also driving conversation.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following news of FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, which has sparked significant price movement and heavy trading volume. The community is discussing potential price targets, short squeezes, and the company's financial outlook, while analysts have increased price targets. Bullish sentiment is fueled by the therapy's potential in a large autoimmune market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with the community citing overall negative sentiment towards AI as a key factor despite the company's prior deal with Microsoft. Some traders point to potential tax-loss harvesting and broader market concerns as contributing to the recent price action. Discussions also involve speculation about future catalysts and whether current levels represent a buying opportunity or further downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Immunome said that the study met its primary endpoint, showing a significant improvement in progression-free survival compared with placebo.</li><li>The trial delivered encouraging efficacy results across key secondary measures, with a confirmed objective response rate at 56% for patients treated with Varegacestat, compared to 9% for those receiving placebo.</li><li>Immunome plans to submit a New Drug Application to the U.S. FDA in the second quarter of 2026.</li></ul>Shares of Immunome Inc. (IMNM)&nbsp;surged more than 12% in on Monday, and reached their highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.<a href="https://stocktwits.com/symbol/IMNM">IMNM</a> was among the top trending tickers on Stocktwits on Monday morning.<h2 class="st-heading-2">Results Of The Trial</h2>Immunome said that the study met its primary endpoint, showing a significant improvement in progression-free survival compared with placebo. According to the report, the Varegacestat inhibitor reduced the risk of disease progression or death by 84%.The trial also delivered encouraging efficacy results across key secondary measures. The confirmed objective response rate was 56% in patients treated with Varegacestat, compared with 9% in those receiving placebo. Patients also experienced substantial tumor shrinkage, with an exploratory analysis showing a median tumor volume reduction of 83%, compared with tumor growth in the placebo group. Improvements in tumor volume reduction and pain intensity were also statistically significant.Varegacestat was generally well tolerated, with most side effects reported as mild to moderate. The most common adverse events included diarrhea, fatigue, rash, cold, and nausea. Based on these results, Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration (USFDA) in the second quarter of 2026.“Desmoid tumors can have a devastating physical and emotional impact on patients given their unpredictable nature and the limitations of current treatment options. The progression-free survival benefit, high response rate and reduction in tumor volume with varegacestat in the RINGSIDE trial are striking. These findings elevate the role of GSIs and confirm varegacestat could become standard of care in the treatment of desmoid tumors,” said Mrinal M. Gounder, sarcoma medical oncologist and drug development specialist at Memorial Sloan Kettering Cancer Center, and RINGSIDE primary investigator.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:910/85;" src="https://news.stocktwits-cdn.com/IMNM_png_16a0580d53.webp" alt="IMNM.png" width="910" height="85"><figcaption>IMNM's Sentiment Meter and Message Volumes at 09:30 a.m. ET on Dec. 15, 2025 | Source: Stocktwits</figcaption></figure>One user expects the stock to potentially double in value.<stembedurl>https://stocktwits.com/Camtanren/message/639163616</stembedurl>Year-to-date, the stock has gained more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/is-the-nasdaq-composite-getting-ready-for-a-short-term-correction/cLe42UrREo4">Is The Nasdaq Composite Getting Ready For A Short-Term Correction? Chart Shows A Lower High And Approach Toward 50-DMA</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Why Is IMNM Stock Rising Today?

Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.

Equity

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global...

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and...

Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM

Birchview Capital LP purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange...

Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC

Redmile Group LLC lowered its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 9.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,872,225 shares...

Natixis Invests $2.13 Million in Immunome, Inc. $IMNM

Natixis acquired a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The...

Immunome (NASDAQ:IMNM) Hits New 12-Month High - Here's Why

Immunome (NASDAQ:IMNM) Sets New 1-Year High - Here's What Happened...

Immunome (NASDAQ:IMNM) Reaches New 1-Year High - Time to Buy?

Immunome (NASDAQ:IMNM) Sets New 1-Year High - Should You Buy...

Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are presently covering the firm, Marketbeat.com...

Kennedy Capital Management LLC Purchases 94,627 Shares of Immunome, Inc. $IMNM

Kennedy Capital Management LLC grew its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 642.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and...

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Current Price	$22.49
Prev Close	$19.57
Open	$22.92
Dividend Yield	0.00%
50-Day Moving Average	$16.82
Beta	1.24
Avg. Volume	1.43M
PE Ratio	-6.62

52-Week High	$20.80
52-Week Low	$5.15
Market Capitalization	$1.79B
EPS (Annual)	-$5.00
Price to Book	6.80
Revenue Per Employee	$76,618.64
Enterprise Value/EBITDA	N/A

IMNM
Immunome Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMNM News

IMNMImmunome Inc